Watson, Mylan Slam FDA Over Generic Celebrex Decision
Watson Laboratories Inc. and Mylan Pharmaceuticals Inc. hit the U.S. Food and Drug Administration with separate lawsuits Monday after the regulator determined another generic-drug maker still has exclusivity rights to market...To view the full article, register now.
Already a subscriber? Click here to view full article